Company Analysis Halozyme Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (49.28%) is higher than the sector average (-22.93%).
- The company's current efficiency (ROE=336%) is higher than the sector average (ROE=9.69%)
Disadvantages
- Price (60.89 $) is higher than fair price (34.89 $)
- Dividends (0%) are below the sector average (0.5448%).
- Current debt level 88.36% has increased over 5 years from 71.14%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Halozyme Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.2% | -20% | 1.4% |
| 90 days | 27.3% | -23.9% | -9.5% |
| 1 year | 49.3% | -22.9% | 10.3% |
HALO vs Sector: Halozyme Therapeutics, Inc. has outperformed the "Healthcare" sector by 72.21% over the past year.
HALO vs Market: Halozyme Therapeutics, Inc. has outperformed the market by 38.94% over the past year.
Stable price: HALO is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: HALO with weekly volatility of 0.9476% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (60.89 $) is higher than the fair price (34.89 $).
Price is higher than fair: The current price (60.89 $) is 42.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.7) is lower than that of the sector as a whole (57.21).
P/E vs Market: The company's P/E (17.7) is lower than that of the market as a whole (48.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (59.49) is higher than that of the sector as a whole (4.65).
P/BV vs Market: The company's P/BV (59.49) is higher than that of the market as a whole (3.42).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.01) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (6.01) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.07) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (15.07) is lower than that of the market as a whole (25.23).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 23.62% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (23.62%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).
5.4. ROE
ROE vs Sector: The company's ROE (336%) is higher than that of the sector as a whole (9.69%).
ROE vs Market: The company's ROE (336%) is higher than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (16.25%) is higher than that of the sector as a whole (0.2896%).
ROA vs Market: The company's ROA (16.25%) is higher than that of the market as a whole (6.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (42.26%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (42.26%) is higher than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5448%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (4.79%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
